Skip to main content Skip to main navigation menu Skip to site footer

Cognitive impairment in cerebral toxoplasmosis with pre-HAART HIV infection: a case report


Background: Dementia can be caused by infection in the central nervous system, primarily by HIV infection. The majority of the symptoms are short-term memory impairment accompanied by concentration and motoric deceleration. Opportunistic infections of Toxoplasma gondii often accompanies and aggravates the cognitive impairment that occurs.

Case: Male, 55-year-old, complained by the family to be forgetful and hard to concentrate since last two weeks and got worse over time. The daily activities of the patient were often disturbed. The awareness, cranial nerve, motor function, sensory, and autonomic were within normal limits. Laboratory tests showed reactive IgG anti-toxoplasma (4520.00 IU / mL) and CD4 128 cells/µL. A non-contrast head CT-Scan showed multiple ill-bordered hypodense lesions with broad peripheral edema in left cerebral hemispheres. Test of cognitive function with MoCA-Ina scored 13 and MMSE scored 19.

Discussion: Dementia in HIV manifests as a collection of symptoms of cognitive and motor impairment that interfere with daily activities. The pathogenesis is thought to be caused by interactions with viral proteins and secondary inflammation. Chronic toxoplasmosis is associated with the incidence of dementia in HIV, which usually occurs when CD4 <200 cells/µL. The underlying pathology of inflammation responsible for neurotransmitter modulation and oxidative stress. HAART administration related to a risk reduction of dementia in HIV. High penetrating antiretroviral lowers viral load better, so it can reliably reduce inflammation while slowing the progression of cognitive impairment.

Conclusion: HIV infection often leads to dementia, either with or without opportunistic infections. Currently, HAART is the only therapy, accompanied by education and follow-up of the patient's cognitive function.


  1. Almeida OP, Lautenschlager NT. Dementia associated with infectious diseases. Int Psychogeriatr. 2005; 17(1): 65-77.
  2. Ghafouri M, et al. HIV-1 associated dementia: symptoms and causes. Retrovirology. 2006: 3(28).
  3. Fischer-Smith T, Rappaport J. Evolving paradigms in the pathogenesis of HIV-1-associated dementia. Expert Rev Mol Med. 2005; 7(27): 1-26.
  4. Imran D, Estiasari R, Maharani K. Infeksi Oportunistik Susuna Saraf Pusat pada AIDS. In: Departemen Neurologi FKUI-RSCM. Buku Ajar Neurologi. Tangerang: Perkisa. 2017; 1(15): 243-7.
  5. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002; 8(2): 115-121.
  6. Heaton R, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010; 75: 2087-96.
  7. Gonzales-Duarte A, Cikurel K, Simpson DM. Selected Neurologic Complications of HIV and Antiretroviral Therapy. The PRN Notebook. 2006; 11(2): 24-9.
  8. Imran D. Neuro-AIDS. In: Pokdi Neuro Infeksi. Infeksi pada Sistem Saraf. Surabaya: Airlangga University Press. 2011: 65-7.
  9. Dalimi A, Abdoli A. Latent Toxoplasmosis and Human. Iranian J Parasitol. 2012; 7(1): 1-17.
  10. Kramer-Hammerle S, et al. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res. 2005, 111(2): 194-213.
  11. Sugianto P. Infeksi Toksoplasmosis pada Sistem Saraf Pusat. In: Pokdi Neuro Infeksi. Infeksi pada Sistem Saraf. Surabaya: Airlangga University Press. 2011: 91-102.
  12. Elleboudy NA, et al. Dementia and toxoplasmosis: Is there a link? Hell J Nucl Med. 2015; 18: 505-28.
  13. Perry CE, et al. Seroprevalence and Serointensity of Latent Toxoplasma gondii in a Sample of Elderly Adults With and Without Alzheimer Disease. Alzheimer Disease & Associated Disorders. 2016; 30(2): 123-6.
  14. Mahami-Oskouei M, et al. Toxoplasmosis and Alzheimer: can Toxoplasma gondii really be introduced as a risk factor in etiology of Alzheimer? Parasitology Research. 2016; 115(8): 3169-74.
  15. Letendre S, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008; 65: 65-70.
  16. Antinori A, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: Different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis. 2005; 41: 1787-93.
  17. Robertson K, Liner J, Meeker R. Antiretroviral neurotoxicity. J Neurovirol. 2012; 18: 388-99.
  18. Giunta B, et al. Antiretroviral medications disrupt microglial phagocytosis of b-amyloid and increase its production by neurons: implications for HIV associated neurocognitive disorders. Mol Brain. 2011; 4: 4-23.

How to Cite

Gunawijaya, D., Kusumastuti, D., Putra, W., & Ekasari, N. (2019). Cognitive impairment in cerebral toxoplasmosis with pre-HAART HIV infection: a case report. Intisari Sains Medis, 10(2).




Search Panel